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Vitamin K intake reduces mortality in people with chronic kidney disease
CL Cheung1,2, S Sahni3, BMY Cheung1, CW Sing2, ICK Wong2
1 Department of Medicine, The University of Hong Kong, Hong Kong
2 Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong
3 IFAR, Hebrew SeniorLife, Harvard Medical School, Boston, United States
Background: Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease 
(CKD), partly due to increased vascular calciﬁcation. Emerging evidence suggests that vitamin K plays a key role 
in preventing vascular calciﬁcation in CKD. However, the relationship between vitamin K intake and mortality 
in people with CKD remains unknown. The objective of this study was to examine the association of vitamin K 
intake with all-cause and CVD mortality in a nationally representative sample aged 20 years or above.
Methods: A total of 3401 participants with CKD from the Third National Health and Nutrition Examination Survey 
were included. Dietary intake was assessed during nutritional examination based on 24-hour dietary recall. 
Vitamin K intake was used in multivariate Cox regression analysis to predict all-cause and CVD mortality. 
Results: During a median follow-up of 13.3 years (37 408 person-years), 1815 and 876 participants died from 
all-cause and CVD causes, respectively. The majority of participants had vitamin K intake lower than the 
recommended intake levels. In multivariable Cox-regression analysis, participants in higher quintiles (quintile 
4-5) of vitamin K intake had signiﬁcantly lower risk of all-cause (hazard ratio [HR] = 0.86; 95% conﬁdence interval 
[CI], 0.75-1; P = 0.046) and CVD mortality (HR = 0.79; 95% CI, 0.64-96; P = 0.021) when compared with quintiles 
1 through 3. Participants with vitamin K intake higher than recommended adequate intake value for vitamin K 
were associated with lower risk of all-cause and CVD mortality. 
Conclusion: These ﬁndings suggest that adequate-to-high level of vitamin K intake reduces CVD and all-cause 
mortality in people with CKD.
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Adiponectin gene variant +276G>T independently predicts incident coronary heart disease in  
men: a 16-year prospective study 
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Sham3,4, KSL Lam1,2 
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Introduction: Adiponectin has been suggested to play a protective role in the development of coronary heart 
disease (CHD). However, recent prospective studies suggested that high adiponectin levels are associated 
with a higher risk of cardiovascular mortality in an established CHD cohort. Study of genetic variants of 
the adiponectin gene (ADIPOQ) may provide more insights into the primary role of adiponectin in CHD 
development. Our objective was to examine the prospective relationship between the genetic variants of 
ADIPOQ and incident CHD in a 16-year prospective population-based cohort of southern Chinese.
Methods: Nine ADIPOQ genetic variants with potential functional relevance or shown to be associated 
with adiponectin levels and/or CHD were genotyped in 2196 subjects from the Hong Kong Cardiovascular 
Risk Factors Prevalence Study (CRISPS), who were free of CHD at baseline. Among these subjects, 184 had 
developed CHD over the 16-year follow-up period.
Results: The ADIPOQ +276G>T variant was found to be independently associated with incident CHD in 
men but not in women, even after adjustments for different sets of conventional cardiovascular risk factors 
(Padjusted = 5.5 x 10
-3 to 0.023; hazard ratio = 1.39 to 1.54). Moreover, the T allele of +276G>T was found to be 
signiﬁcantly associated with reduced plasma adiponectin level (P = 0.027) in 1676 subjects with available plasma 
samples for analysis.
Conclusion: This study supports a protective role of adiponectin in the development of CHD in the general 
population.
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